We have released new research in collaboration with the University of New South Wales which has revealed the median total cost for people living with macular disease, who also receive sight-saving eye injections, is 12 percent* ($3,621) of the annual government pension payment.
By The Hon. Jillian Skinner, AM, former NSW Minister for Health.This article was originally published by News Corp.
Macular Disease Foundation Australia calls on the next Federal Government to bulk-bill sight-saving eye injections for pensioners; with the potential for creating a $140 million cost-saving per year.
Macular Disease Foundation Australia (MDFA) has announced the launch of its inaugural MDFA 25th Anniversary Award
The Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE® (pegcetacoplan) is welcome news, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease.
Welcome to our final Vision Voice newsletter for the year.
MDFA has received a positive response from the people participating in our new Eye Connect support service.
Macular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.
The Federal Government has announced that from 1 July 2025, people receiving sight-saving eye (intravitreal) injections to treat macular disease will no longer receive health fund benefits for this treatment if it is performed in private hospitals and day surgeries.